(July 2, 2018) Last month the American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, IL. Thirty nine thousand people from around the world attend to learn about the latest in cancer research. Ovarian cancer survivor and research advocate Annie Ellis attended the meeting and wrote a report highlighting some of the research presented during the conference, including that which relates to surgical interventions, clinical trials, the genetic component to treatment strategies, and survivorship.
Related Topics
OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued
OCRA Invests More than $10.8 Million Toward Research, Part of $14.5 Million Commitment in 2025
In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy. This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued